Regarding the modified IL-15-derived products, N-803 (formerly known as ALT-803), a compound developed by binding an IL-15 mutant to a soluble dimeric IL-15Ra-Fc fusion protein, has been proven capable of expanding NK and CD8 T cells and of inducing a significantly higher anti-tumor activity than rIL-15. This evidence concerns the gene IL15 and neoplasm.